Division of Gastroenterology, Washington University School of Medicine, St Louis, MO, USA; Department of Psychiatry, Washington University School of Medicine, 915 North Grand Boulevard, St Louis, MO 63106, USA; St. Louis Veterans Affairs Medical Center, St Louis, MO, USA.
Gastroenterol Clin North Am. 2021 Sep;50(3):611-637. doi: 10.1016/j.gtc.2021.04.003.
Diarrhea-predominant irritable bowel syndrome is a common functional gastrointestinal disorder that manifests with abdominal pain and diarrheal bowel patterns, without structural explanation. Diarrhea-predominant irritable bowel syndrome is a heterogeneous condition resulting from diverse pathophysiologic processes. Treatment strategies with varied mechanisms of action are beneficial in its management. The clinician must become familiar with a multi-dimensional approach to irritable bowel syndrome. The 3 approved medications are central to disease management. Effective treatment uses off-label medications and emerging therapies and a growing number of over-the-counter and supplemental agents to optimize symptom improvement for the patient with diarrhea-predominant irritable bowel syndrome.
腹泻为主型肠易激综合征是一种常见的功能性胃肠疾病，其特征为腹痛和腹泻型肠易激综合征，无结构解释。腹泻为主型肠易激综合征是一种异质性疾病，由多种病理生理过程引起。作用机制不同的治疗策略对其管理有益。临床医生必须熟悉肠易激综合征的多维方法。3 种批准的药物是疾病管理的核心。有效的治疗方法使用非标签药物和新兴疗法，以及越来越多的非处方和补充剂，以优化腹泻为主型肠易激综合征患者的症状改善。
